SEARCH

SEARCH BY CITATION

References

  • Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O’Marcaigh, A., Wynn, R., Stevens, R., Addison, M., King, D., Stewart, B., Gibson, B., Roberts, I. & Vyas, P. (2004) Natural history of GATA1 mutations in Down syndrome. Blood, 103, 24802489.
  • Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O.A., Mann, G., Binder, V., Borkhardt, A., Kempski, H., Trka, J., Bielorei, B., Avigad, S., Stark, B., Smith, O., Dastugue, N., Bourquin, J.P., Tal, N.B., Green, A.R. & Izraeli, S. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet, 372, 14841492.
  • Bourquin, J.P., Subramanian, A., Langebrake, C., Reinhardt, D., Bernard, O., Ballerini, P., Baruchel, A., Cave, H., Dastugue, N., Hasle, H., Kaspers, G.L., Lessard, M., Michaux, L., Vyas, P., Van Wering, E., Zwaan, C.M., Golub, T.R. & Orkin, S.H. (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 103, 33393344.
  • Carpenter, E., Valverde-Garduno, V., Sternberg, A., Mitchell, C., Roberts, I., Vyas, P. & Vora, A. (2005) GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. British Journal of Haematology, 128, 548551.
  • Chou, S.T., Opalinska, J.B., Yao, Y., Fernandes, M.A., Kalota, A., Brooks, J.S., Choi, J.K., Gewirtz, A.M., Danet-Desnoyers, G.A., Nemiroff, R.L. & Weiss, M.J. (2008) Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood, 112, 45034506.
  • Creutzig, U., Ritter, J., Vormoor, J., Ludwig, W.D., Niemeyer, C., Reinisch, I., Stollmann-Gibbels, B., Zimmermann, M. & Harbott, J. (1996) Myelodysplasia and acute myelogenous leukemia in Down’s syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia, 10, 16771686.
  • Creutzig, U., Reinhardt, D., Diekamp, S., Dworzak, M., Stary, J. & Zimmermann, M. (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia, 19, 13551360.
  • Cushing, T., Clericuzio, C.L., Wilson, C.S., Taub, J.W., Ge, Y., Reichard, K.K. & Winter, S.S. (2006) Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. Journal of Pediatrics, 148, 687689.
  • David, O., Fiorucci, G.C., Tosi, M.T., Altare, F., Valori, A., Saracco, P., Asinardi, P., Ramenghi, U. & Gabutti, V. (1996) Hematological studies in children with Down syndrome. Pediatric Hematology and Oncology, 13, 271275.
  • De Vita, S., Mulligan, C., McElwaine, S., Dagna-Bricarelli, F., Spinelli, M., Basso, G., Nizetic, D. & Groet, J. (2007) Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome. British Journal of Haematology, 137, 337341.
  • Delabar, J.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., Noel, B. & Sinet, P.M. (1993) Molecular mapping of twenty-four features of Down syndrome on chromosome 21. European Journal of Human Genetics, 1, 114124.
  • Elagib, K.E., Racke, F.K., Mogass, M., Khetawat, R., Delehanty, L.L. & Goldfarb, A.N. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood, 101, 43334341.
  • Forestier, E., Izraeli, S., Beverloo, B., Haas, O., Pession, A., Michalova, K., Stark, B., Harrison, C.J., Teigler-Schlegel, A. & Johansson, B. (2008) Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood, 111, 15751583.
  • Frost, B.M., Gustafsson, G., Larsson, R., Nygren, P. & Lonnerholm, G. (2000) Cellular cytotoxic drug sensitivity in children with acute leukemia and Down’s syndrome: an explanation to differences in clinical outcome? Leukemia, 14, 943944.
  • Galante, M., Jani, H., Vanes, L., Daniel, H., Fisher, E.M., Tybulewicz, V.L., Bliss, T.V. & Morice, E. (2009) Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Human Molecular Genetics, 18, 14491463.
  • Gamis, A.S. (2005) Acute myeloid leukemia and Down syndrome evolution of modern therapy – state of the art review. Pediatric Blood & Cancer, 44, 1320.
  • Gamis, A.S., Woods, W.G., Alonzo, T.A., Buxton, A., Lange, B., Barnard, D.R., Gold, S. & Smith, F.O. (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. Journal of Clinical Oncology, 21, 34153422.
  • Garzon, R., Pichiorri, F., Palumbo, T., Iuliano, R., Cimmino, A., Aqeilan, R., Volinia, S., Bhatt, D., Alder, H., Marcucci, G., Calin, G.A., Liu, C.G., Bloomfield, C.D., Andreeff, M. & Croce, C.M. (2006) MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 50785083.
  • Ge, Y., Dombkowski, A.A., LaFiura, K.M., Tatman, D., Yedidi, R.S., Stout, M.L., Buck, S.A., Massey, G., Becton, D.L., Weinstein, H.J., Ravindranath, Y., Matherly, L.H. & Taub, J.W. (2006) Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood, 107, 15701581.
  • Girodon, F., Favre, B., Couillaud, G., Carli, P.M., Parmeland, C. & Maynadie, M. (2000) Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21. Cytometry, 42, 118122.
  • Groet, J., McElwaine, S., Spinelli, M., Rinaldi, A., Burtscher, I., Mulligan, C., Mensah, A., Cavani, S., Dagna-Bricarelli, F., Basso, G., Cotter, F.E. & Nizetic, D. (2003) Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid disorder. Lancet, 361, 16171620.
  • Hasle, H., Clemmensen, I.H. & Mikkelsen, M. (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet, 355, 165169.
  • Hasle, H., Niemeyer, C.M., Chessells, J.M., Baumann, I., Bennett, J.M., Kerndrup, G. & Head, D.R. (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277282.
  • Hasle, H., Abrahamsson, J., Arola, M., Karow, A., O’Marcaigh, A., Reinhardt, D., Webb, D.K., Van Wering, E., Zeller, B., Zwaan, C.M. & Vyas, P. (2008) Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia, 22, 14281430.
  • Heald, B., Hilden, J.M., Zbuk, K., Norton, A., Vyas, P., Theil, K.S. & Eng, C. (2007) Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nature Clinical Practice. Oncology, 4, 433438.
  • Henry, E., Walker, D., Wiedmeier, S.E. & Christensen, R.D. (2007) Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. American Journal of Medical Genetics. Part A, 143, 4250.
  • De Hingh, Y.C., Van Der Vossen, P.W., Gemen, E.F., Mulder, A.B., Hop, W.C., Brus, F. & De Vries, E. (2005) Intrinsic abnormalities of lymphocyte counts in children with down syndrome. Journal of Pediatrics, 147, 744747.
  • Hirose, Y., Kudo, K., Kiyoi, H., Hayashi, Y., Naoe, T. & Kojima, S. (2003) Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down’s syndrome. Leukemia, 17, 22502252.
  • Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W. & Zipursky, A. (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 43014304.
  • Hollanda, L.M., Lima, C.S., Cunha, A.F., Albuquerque, D.M., Vassallo, J., Ozelo, M.C., Joazeiro, P.P., Saad, S.T. & Costa, F.F. (2006) An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics, 38, 807812.
  • Hoyme, F. (2004) Chromosomal clinical abnormalities. In: Nelson’s Textbook of Paediatrics, pp. 384. WB Saunders, Philadelphia.
  • Karandikar, N.J., Aquino, D.B., McKenna, R.W. & Kroft, S.H. (2001) Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. American Journal of Clinical Pathology, 116, 204210.
  • Kearney, L., Gonzalez De Castro, D., Yeung, J., Procter, J., Horsley, S.W., Eguchi-Ishimae, M., Bateman, C.M., Anderson, K., Chaplin, T., Young, B.D., Harrison, C.J., Kempski, H., Wai, E.S.C., Ford, A.M. & Greaves, M. (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood, 113, 646648.
  • Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M.M. & Crispino, J.D. (2008) Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood, 111, 767775.
  • Kivivuori, S.M., Rajantie, J. & Siimes, M.A. (1996) Peripheral blood cell counts in infants with Down’s syndrome. Clinical Genetics, 49, 1519.
  • Kiyoi, H., Yamaji, S., Kojima, S. & Naoe, T. (2007) JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia, 21, 574576.
  • Klusmann, J.H., Reinhardt, D., Hasle, H., Kaspers, G.J., Creutzig, U., Hahlen, K., Van Den Heuvel-Eibrink, M.M. & Zwaan, C.M. (2007) Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down’s syndrome. Leukemia, 21, 15841587.
  • Klusmann, J.H., Creutzig, U., Zimmermann, M., Dworzak, M., Jorch, N., Langebrake, C., Pekrun, A., Macakova-Reinhardt, K. & Reinhardt, D. (2008) Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood, 111, 29912998.
  • Kuhl, C., Atzberger, A., Iborra, F., Nieswandt, B., Porcher, C. & Vyas, P. (2005) GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1. Molecular and Cellular Biology, 25, 85928606.
  • Lange, B. (2000) The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome. British Journal of Haematology, 110, 512524.
  • Lange, B.J., Kobrinsky, N., Barnard, D.R., Arthur, D.C., Buckley, J.D., Howells, W.B., Gold, S., Sanders, J., Neudorf, S., Smith, F.O. & Woods, W.G. (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891. Blood, 91, 608615.
  • Langebrake, C., Creutzig, U. & Reinhardt, D. (2005) Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klinische Padiatrie, 217, 126134.
  • Lejeune, J., Gautier, M. & Turpin, R. (1959) [Study of somatic chromosomes from 9 mongoloid children.]. Comptes rendus hebdomadaires des séances de l’Académie des sciences, 248, 17211722.
  • Li, Z., Godinho, F.J., Klusmann, J.H., Garriga-Canut, M., Yu, C. & Orkin, S.H. (2005) Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genetics, 37, 613619.
  • Lightfoot, J., Hitzler, J.K., Zipursky, A., Albert, M. & Macgregor, P.F. (2004) Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia, 18, 16171623.
  • Lyle, R., Bena, F., Gagos, S., Gehrig, C., Lopez, G., Schinzel, A., Lespinasse, J., Bottani, A., Dahoun, S., Taine, L., Doco-Fenzy, M., Cornillet-Lefebvre, P., Pelet, A., Lyonnet, S., Toutain, A., Colleaux, L., Horst, J., Kennerknecht, I., Wakamatsu, N., Descartes, M., Franklin, J.C., Florentin-Arar, L., Kitsiou, S., Ait Yahya-Graison, E., Costantine, M., Sinet, P.M., Delabar, J.M. & Antonarakis, S.E. (2008) Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. European Journal of Human Genetics, 17, 454466.
  • Malinge, S., Ragu, C., Della-Valle, V., Pisani, D., Constantinescu, S.N., Perez, C., Villeval, J.L., Reinhardt, D., Landman-Parker, J., Michaux, L., Dastugue, N., Baruchel, A., Vainchenker, W., Bourquin, J.P., Penard-Lacronique, V. & Bernard, O.A. (2008) Activating mutations in human acute megakaryoblastic leukemia. Blood, 112, 42204226.
  • Malinge, S., Izraeli, S. & Crispino, J.D. (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 113, 26192628.
  • Malkin, D., Brown, E.J. & Zipursky, A. (2000) The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genetics and Cytogenetics, 116, 15.
  • Massey, G.V., Zipursky, A., Chang, M.N., Doyle, J.J., Nasim, S., Taub, J.W., Ravindranath, Y., Dahl, G. & Weinstein, H.J. (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood, 107, 46064613.
  • McElwaine, S., Mulligan, C., Groet, J., Spinelli, M., Rinaldi, A., Denyer, G., Mensah, A., Cavani, S., Baldo, C., Dagna-Bricarelli, F., Hann, I., Basso, G., Cotter, F.E. & Nizetic, D. (2004) Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down’s syndrome, revealing PRAME as a specific discriminating marker. British Journal of Haematology, 125, 729742.
  • Muntean, A.G. & Crispino, J.D. (2005) Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood, 106, 12231231.
  • Muramatsu, H., Kato, K., Watanabe, N., Matsumoto, K., Nakamura, T., Horikoshi, Y., Mimaya, J., Suzuki, C., Hayakawa, M. & Kojima, S. (2008) Risk factors for early death in neonates with Down syndrome and transient leukaemia. British Journal of Haematology, 142, 610615.
  • Norton, A., Fisher, C., Liu, H., Wen, Q., Mundschau, G., Fuster, J.L., Hasle, H., Zeller, B., Webb, D.K., O’Marcaigh, A., Sorrell, A., Hilden, J., Gamis, A., Crispino, J.D. & Vyas, P. (2007) Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood, 110, 10771079.
  • O’Doherty, A., Ruf, S., Mulligan, C., Hildreth, V., Errington, M.L., Cooke, S., Sesay, A., Modino, S., Vanes, L., Hernandez, D., Linehan, J.M., Sharpe, P.T., Brandner, S., Bliss, T.V., Henderson, D.J., Nizetic, D., Tybulewicz, V.L. & Fisher, E.M. (2005) An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science, 309, 20332037.
  • Patja, K., Pukkala, E., Sund, R., Iivanainen, M. & Kaski, M. (2006) Cancer incidence of persons with Down syndrome in Finland: a population-based study. International Journal of Cancer, 118, 17691772.
  • Pine, S.R., Guo, Q., Yin, C., Jayabose, S., Druschel, C.M. & Sandoval, C. (2007) Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood, 110, 21282131.
  • Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J.L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., Kerckaert, J.P., Cosson, A. & Fenaux, P. (2000) High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 96, 28622869.
  • Rainis, L., Bercovich, D., Strehl, S., Teigler-Schlegel, A., Stark, B., Trka, J., Amariglio, N., Biondi, A., Muler, I., Rechavi, G., Kempski, H., Haas, O.A. & Izraeli, S. (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981986.
  • Rao, A., Hills, R.K., Stiller, C., Gibson, B.E., De Graaf, S.S., Hann, I.M., O’Marcaigh, A., Wheatley, K. & Webb, D.K. (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. British Journal of Haematology, 132, 576583.
  • Ravindranath, Y. (2003) Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. Journal of Clinical Oncology, 21, 33853387.
  • Robertson, M., De Jong, G. & Mansvelt, E. (2003) Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks’ gestation with Down syndrome: case report and review of the literature. Ultrasound in Obstetrics and Gynecology, 21, 486489.
  • Roizen, N.J. & Patterson, D. (2003) Down’s syndrome. Lancet, 361, 12811289.
  • Ronan, A., Fagan, K., Christie, L., Conroy, J., Nowak, N.J. & Turner, G. (2007) Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. Journal of Medical Genetics, 44, 448451.
  • Roper, R.J. & Reeves, R.H. (2006) Understanding the basis for Down syndrome phenotypes. PLoS Genetics, 2, e50.
  • Ross, J.A., Spector, L.G., Robison, L.L. & Olshan, A.F. (2005) Epidemiology of leukemia in children with Down syndrome. Pediatric Blood & Cancer, 44, 812.
  • Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, S., Migita, M., Morinaga, S., Nakano, T., Endo, M., Kojima, S., Kiyoi, H., Mano, H. & Ito, E. (2008) Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. British Journal of Haematology, 141, 681688.
  • Smrcek, J.M., Baschat, A.A., Germer, U., Gloeckner-Hofmann, K. & Gembruch, U. (2001) Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound in Obstetrics and Gynecology, 17, 403409.
  • Stachura, D.L., Chou, S.T. & Weiss, M.J. (2006) Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood, 107, 8797.
  • Stankiewicz, M.J. & Crispino, J.D. (2009) ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. Blood, 113, 33373347.
  • Starc, T.J. (1992) Erythrocyte macrocytosis in infants and children with Down syndrome. Journal of Pediatrics, 121, 578581.
  • Taub, J.W. & Ge, Y. (2005) Down syndrome, drug metabolism and chromosome 21. Pediatric Blood & Cancer, 44, 3339.
  • Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G. & Ravindranath, Y. (1996) Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood, 87, 33953403.
  • Taub, J.W., Stout, M.L., Buck, S.A., Huang, X., Vega, R.A., Becton, D.L. & Ravindranath, Y. (1997) Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin. Leukemia, 11, 15941595.
  • Taub, J.W., Huang, X., Matherly, L.H., Stout, M.L., Buck, S.A., Massey, G.V., Becton, D.L., Chang, M.N., Weinstein, H.J. & Ravindranath, Y. (1999) Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 94, 13931400.
  • Taub, J.W., Huang, X., Ge, Y., Dutcher, J.A., Stout, M.L., Mohammad, R.M., Ravindranath, Y. & Matherly, L.H. (2000) Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Research, 60, 64216426.
  • Tunstall-Pedoe, O., Roy, A., Karadimitris, A., De La Fuente, J., Fisk, N.M., Bennett, P., Norton, A., Vyas, P. & Roberts, I. (2008) Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood, 112, 45074511.
  • Vyas, P. & Crispino, J.D. (2007) Molecular insights into Down syndrome-associated leukemia. Current Opinion in Pediatrics, 19, 914.
  • Walters, D.K., Mercher, T., Gu, T.L., O’Hare, T., Tyner, J.W., Loriaux, M., Goss, V.L., Lee, K.A., Eide, C.A., Wong, M.J., Stoffregen, E.P., McGreevey, L., Nardone, J., Moore, S.A., Crispino, J., Boggon, T.J., Heinrich, M.C., Deininger, M.W., Polakiewicz, R.D., Gilliland, D.G. & Druker, B.J. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10, 6575.
  • Watts, T.L., Murray, N.A. & Roberts, I.A. (1999) Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatric Research, 46, 2832.
  • Webb, D., Roberts, I. & Vyas, P. (2007) Haematology of Down syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition, 92, F503F507.
  • Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. & Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148152.
  • Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M. & Ito, E. (2003) Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood, 102, 29602968.
  • Xu, G., Kanezaki, R., Toki, T., Watanabe, S., Takahashi, Y., Terui, K., Kitabayashi, I. & Ito, E. (2006) Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia, 20, 10021008.
  • Yamada, S., Hongo, T., Okada, S., Watanabe, C., Fujii, Y., Hori, H., Yazaki, M., Hanada, R. & Horikoshi, Y. (2001) Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. International Journal of Hematology, 74, 428436.
  • Yumura-Yagi, K., Hara, J., Kurahashi, H., Nishiura, T., Kaneyama, Y., Osugi, Y., Sakata, N., Inoue, M., Tawa, A., Okada, S. & Kawa-Ha, K. (1992) Mixed phenotype of blasts in acute megakaryocytic leukaemia and transient abnormal myelopoiesis in Down’s syndrome. British Journal of Haematology, 81, 520525.
  • Zeller, B., Gustafsson, G., Forestier, E., Abrahamsson, J., Clausen, N., Heldrup, J., Hovi, L., Jonmundsson, G., Lie, S.O., Glomstein, A. & Hasle, H. (2005) Acute leukaemia in children with Down syndrome: a population-based Nordic study. British Journal of Haematology, 128, 797804.
  • Zipursky, A. (2000) Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatric Research, 47, 704.
  • Zipursky, A. (2003) Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21. British Journal of Haematology, 120, 930938.
  • Zipursky, A., Poon, A. & Doyle, J. (1992) Leukemia in Down syndrome: a review. Pediatric Hematology and Oncology, 9, 139149.
  • Zwaan, C.M., Kaspers, G.J., Pieters, R., Hahlen, K., Huismans, D.R., Zimmermann, M., Harbott, J., Slater, R.M., Creutzig, U. & Veerman, A.J. (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 100, 33523360.